Clinical trial
Assessment of Grazax® Treatment Compliance
NCT00293046 · ALK-Abelló A/S, Industry · Completed
Key facts
| NCT number | NCT00293046 |
|---|---|
| Title | Assessment of Grazax® Treatment Compliance |
| Official title | A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis |
| Lead sponsor | ALK-Abelló A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Biological |
| Interventions | ALK Grass tablet - use of compliance device |
| Enrollment | 500 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Feb 17, 2006 |
| Last update posted | Sep 30, 2008 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: